
IT director Chris Roche joins Aridhia
pharmafile | May 30, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | EMC, IT, Roche, aridhia
Health tech informatics firm Aridhia has appointed Chris Roche to a newly-created post on its executive team as chief commercial officer.
Roche joins Aridhia from IT firm EMC where he worked for 14 years. His background is in computing and his specialist area is artificial intelligence.
During 14 years at EMC, Roche held a number of positions at senior director level and most recently served as EMEA CTO. His other roles included director of Greenplum UK, EMC’s big data business, senior director of technology services, country manager for EMC in Ireland.
Before joining EMC, Roche worked for Accenture, and also spent three years at ICL working in the chief executive’s office. He started his career at IBM.
Roche says: “Working for Aridhia is a fantastically exciting opportunity for me. We have the chance to do something truly important in the management of chronic disease and collaborative research. Everyone at Aridhia shares that hope and it was a critical factor in my decision to move.”
David Sibbald, Aridhia’s chief executive adds: “We are very pleased that Chris is joining us. We have worked closely with him over the past two years, giving him a unique insight into our business and understanding of the challenges we face. His commercial and business acumen – in the context of what we do – will allow us to enter new markets rapidly as we launch new products.”
Related Content

NNIT partners with global biopharma company for regulatory registration management
NNIT, a Danish provider of digital software and IT services, has entered a long-term strategic …

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

Roche candidate shows early promise for treating haemophilia A
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …






